Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 7503-7503 ◽  
Author(s):  
R. Rosell ◽  
R. Gervais ◽  
A. Vergnenegre ◽  
B. Massuti ◽  
E. Felip ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document